Cargando…
The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion
BACKGROUND: Drug-disease interactions negatively affect the benefit/risk ratio of drugs for specific populations. In these conditions drugs should be avoided, adjusted, or accompanied by extra monitoring. The motivation for many drug-disease interactions in the Summary of Product Characteristics (Sm...
Autores principales: | van Tongeren, Justine M. Z., Harkes-Idzinga, S. Froukje, van der Sijs, Heleen, Atiqi, Roya, van den Bemt, Bart J. F., Draijer, L. Willem, Hiel, Deline, Kerremans, Adrian, Kremers, Bart, de Leeuw, Marc, Olthoff, Marleen V., Pham, T. Kim-Loan, Valentijn-Robertz, Ricky, Tsoi, Kayan, Wichers, Iris, de Wit, Maaike, Borgsteede, Sander D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243438/ https://www.ncbi.nlm.nih.gov/pubmed/32499701 http://dx.doi.org/10.3389/fphar.2020.00707 |
Ejemplares similares
-
Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis
por: Weersink, Rianne A., et al.
Publicado: (2018) -
Safe use of proton pump inhibitors in patients with cirrhosis
por: Weersink, Rianne A., et al.
Publicado: (2018) -
The use of a clinical decision support tool to assess the risk of QT drug–drug interactions in community pharmacies
por: Berger, Florine A., et al.
Publicado: (2021) -
Development and validation of a tool to assess the risk of QT drug-drug interactions in clinical practice
por: Berger, Florine A., et al.
Publicado: (2020) -
Dynamics of the QTc interval over a 24‐h dose interval after start of intravenous ciprofloxacin or low‐dose erythromycin administration in ICU patients
por: Berger, Florine A., et al.
Publicado: (2021)